Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 13/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL412151 | 0.91 | MAP3K14 (0.47) | MAP3K14PIK3CDPIK3R1IGF1RCDK4 | |
| SCHEMBL411998 | 0.91 | MAP3K14 (0.47) | MAP3K14PIK3CDPIK3R1IGF1RCDK4 | |
| SCHEMBL413617 | 0.89 | TGFBR1 (0.50) | MAP3K14PIK3CDPIK3R1IGF1RCDK4 | |
| SCHEMBL413066 | 0.88 | MAP3K14 (0.45) | MAP3K14PIK3CDPIK3R1IGF1RCDK4 | |
| SCHEMBL409977 | 0.88 | MAP3K14 (0.45) | MAP3K14PIK3CDPIK3R1IGF1RCDK4 | |
| SCHEMBL415146 | 0.88 | MAP3K14 (0.50) | MAP3K14PIK3CDPIK3R1IGF1RCDK4 | |
| SCHEMBL412000 | 0.88 | MAP3K14 (0.50) | MAP3K14PIK3CDPIK3R1IGF1RCDK4 | |
| Hydroxyamine SCHEMBL5265983 | 0.88 | MAP3K14 (0.50) | MAP3K14PIK3CDPIK3R1IGF1RCDK4 | |
| SCHEMBL409368 | 0.87 | TGFBR1 (0.42) | MAP3K14PIK3CDPIK3R1IGF1RCDK4 | |
| SCHEMBL5265992 | 0.87 | MAP3K14 (0.47) | MAP3K14PIK3CDPIK3R1IGF1RCDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | claimed |
| US-20060135517-A1 | Imidazolopyridines and methods of making and using the same | BIOGEN IDEC MA INC. | 2006-06-22 | — | — | US | claimed |
| EP-1546112-A4 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | claimed |
| EP-1546112-A2 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2004021989-A2 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2004-03-18 | — | — | WO | claimed |
| US-20140120621-A1 | TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-8603818-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-8298825-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120021519-A1 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2008013928-A2 | TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR | BIOGEN IDEC MA INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20060135517-A1 | Imidazolopyridines and methods of making and using the same | BIOGEN IDEC MA INC. | 2006-06-22 | — | — | US | disclosed |
| EP-1546112-A4 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1546112-A2 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004021989-A2 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135517-A1 | Imidazolopyridines and methods of making and using the same | ALK, ACVR1, ACVRL1 | MAP3K14 555/4885PIK3CD 825/4885PIK3R1 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.